### Sofosbuvir

**Section:** 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.4. Antihepatitis medicines > 6.4.4.2. Medicines for hepatitis C > 6.4.4.2.1. Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

**Indication**
Chronic hepatitis C

**INN**
Sofosbuvir

**Medicine type**
Chemical agent

**List type**
Core

**Additional notes**
Pangenotypic when used in combination with daclatasvir or ravidasvir.

**Formulations**
Oral > Solid: 400 mg; 200 mg

**EML status history**
- First added in 2015 (TRS 994)
- Changed in 2019 (TRS 1021)
- Changed in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
Medicines within the same pharmacological class can be used

**Therapeutic alternatives limitations**
Pangenotypic direct-acting antiviral combinations

**Therapeutic alternatives limitations for EMLc**
Pangenotypic direct-acting antiviral combinations

**Patent information**
Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org

**Wikipedia**
Sofosbuvir

**DrugBank**
Sofosbuvir

---

### Summary of evidence and Expert Committee recommendations

The note associated with the listing of sofosbuvir was updated following the recommendation to include ravidasvir on the EML.